CHICAGO — In this video, Sham Mailankody, MBBS, highlights data from a study of carfilzomib, lenalidomide and dexamethasone, with or without daratumumab, for patients with newly diagnosed multiple myeloma.
“Four drugs appear to be better than three drugs, even in the context of carfilzomib,” Mailankody, a myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center, said. “I think, adding to the large volume of data that are now available, that most patients with newly diagnosed myeloma should be treated with four drugs.”
Landgren CO, et al.